Upregulated TNF Expression 1 Year After Bariatric Surgery Reflects a Cachexia-Like State in Subcutaneous Adipose Tissue

Alexander Jürets 1 · Bianca Karla Itariu 1 · Magdalena Keindl 1 · Gerhard Prager 2 · Felix Langer 2 · Viktor Grablowitz 3 · Maximilian Zeyda 1,4 · Thomas Michael Stulnig 1

Published online: 29 November 2016 © The Author(s) 2016. This article is published with open access at Springerlink.com

Abstract

Background Adipose tissue dysfunction contributes to obesity-associated chronic diseases. In the first year after bariatric surgery, obese patients significantly improve their metabolic status upon losing weight. We aimed to investigate whether changes in subcutaneous adipose tissue gene expression reflect a restoration of a healthy lean phenotype after bariatric surgery.

Methods Thirty-one severely obese patients (BMI ≥ 40 kg/m²) were examined before and after surgery. Subcutaneous adipose tissue (SAT) was collected during and 1 year after bariatric surgery. SAT from 20 matched lean and overweight patients (BMI < 30 kg/m²) was collected during elective abdominal surgery. Baseline characteristics and SAT gene expression relevant to glucose and lipid metabolism, inflammation, and apoptosis were analyzed.

Results After surgery, mean BMI decreased from 46.1 ± 6.3 to 31.1 ± 5.7 kg/m² and homeostasis model assessment of insulin resistance from 5.4 ± 5.3 to 0.8 ± 0.8. SAT expression of most analyzed inflammatory cytokines, growth factors, and metabolic and cell surface markers was greatly downregulated even compared to the lean cohort. In contrast, gene expression of TNF and CASP3 was significantly upregulated. Elastic net regression analysis showed that fasting glucose levels and CASP3 predicted increased TNF expression in the post-obese group.

Conclusions Gene expression patterns in SAT 1 year after bariatric surgery point to a reduced inflammation. The unexpected high TNF expression in SAT of post-obese subjects is most likely not an indicator for inflammation, but rather an indicator for increased lipolysis and adipose tissue catabolism. Notably, after bariatric surgery SAT gene expression reflects a cachexia-like phenotype and differs from the lean state.

Keywords Tumor necrosis factor · Bariatric surgery · Subcutaneous adipose tissue · Gene expression · Weight loss

Introduction

Adipose tissue participates in whole-body metabolism not just by energy storage. It is an endocrine organ and an important site for inflammatory crosstalk and immune response. Subcutaneous adipose tissue (SAT) is the largest adipose compartment for most humans and the primary site for lipid storage. Excess caloric intake per se causes an activation of resident immune cells in the adipose tissue, to which other immune cells are attracted from the circulation [1]. Long-term overnutrition leads to a chronic low-grade inflammation, which promotes insulin resistance, for instance via insulin receptor substrate 2 (IRS2) downregulation in SAT [2] and thus precedes type 2 diabetes mellitus (T2DM) and other metabolic disorders [3]. In the development of chronic inflammation, T cells induce the infiltration and inflammatory
The hemoglobin A1c level improved significantly following bariatric surgery has been frequently reported: 1 year [14]. Long-term remission of T2DM in obese patients undergoing bariatric surgery resembles in some cases of cachexia -1 year after surgery was reduced compared to conservative therapy [15, 16]. On the other hand, weight loss following bariatric surgery is key to restoring insulin sensitivity and reducing cardiovascular risk. Currently, bariatric surgery is the most sustainable treatment option, superior to lifestyle interventions in terms of weight maintenance and risk reduction [14]. Long-term remission of T2DM in obese patients undergoing bariatric surgery has been frequently reported: 1 year after surgery, the hemoglobin A1c level improved significantly, and disease-related mortality was reduced compared to conservative therapy [15, 16]. On the other hand, weight loss following bariatric surgery resembles in some cases of cachexia [17]. Although cachexia and obesity are on opposite sides of the weight spectrum, they display many similarities as both are characterized by increased adipose tissue inflammation and insulin resistance [11–13].

Weight loss is key to restoring insulin sensitivity and reducing cardiovascular risk. Currently, bariatric surgery is the most sustainable treatment option, superior to lifestyle interventions in terms of weight maintenance and risk reduction [14].

Material and Methods

Ethical Statement

The trial has been performed in accordance to the 1964 Declaration of Helsinki and its latter amendments and with the Good Clinical Practice guidelines at the Department of Medicine III, Medical University of Vienna. All participants provided informed written consent prior to their inclusion in the study. The trial had been approved by the Ethics Committee of the Medical University of Vienna (EK-Nr. 488/2006, EK 275/2006, and EK-Nr. 963/2009) and by the Ethics Committee of the Göttlicher Heiland Hospital (EK-Nr. E10-N01-01) and was conducted at the Clinical Research Unit of the Division of Endocrinology and Metabolism, Department of Medicine III, Medical University of Vienna.

Study Population

Morbidly obese patients (BMI > 40 kg/m²) prior to and 1 year after bariatric surgery were compared to a group of lean and overweight patients. We investigated metabolic parameters and SAT gene expression of 31 morbidly obese patients (BMI > 40 kg/m²) before and approximately 1 year after elective bariatric surgery (follow-up time 419 ± 58 days). Adipose tissue and serum samples were collected within another study from n = 20 lean and overweight donors (BMI < 30 kg/m²) undergoing elective abdominal surgery either at the Department of Surgery from the Medical University of Vienna or the Hospital Göttlicher Heiland in Vienna. Results have been published elsewhere [19, 20]. For comparison of gene expression, a subgroup of n = 20 obese patients matched for age and sex with the lean and overweight were analyzed.

Obese patients were advised to maintain usual physical activity at a constant level. No intensive exercise routines were documented. All obese patients participated in previous trials by our group and metabolic changes 1 year after bariatric surgery have been presented elsewhere [21]. Briefly, 20–65-year-old patients scheduled to undergo bariatric surgery or elective abdominal surgery were eligible for inclusion if their BMI was >40 kg/m² before surgery for the obese group and <30 kg/m² for the lean and overweight control group, and their fasting plasma glucose <126 mg/dl and 2-h plasma glucose after a 75-g oral-glucose tolerance test <200 mg/dl. Exclusion criteria included acute illness within the past 14 days or severe chronic illness such as active malignancies; acquired immunodeficiency (HIV infection, AIDS); significant liver, cardiovascular, renal, pulmonary or thyroid disease; anemia; inborn or acquired bleeding disorders; as well as pregnancy or breastfeeding. Anthropometric parameters were determined at inclusion and at the 1-year follow-up visit after bariatric surgery. All patients were Caucasian.
Collection of Subcutaneous Adipose Tissue

All bariatric surgeries (26 Roux-en-Y-gastric bypass (RYGB), three sleeve resections, and two gastric bandings) had been performed at the Department of Surgery of the Medical University of Vienna. Samples of SAT were collected by excision from the umbilical area during surgery. Other elective abdominal surgeries had been performed at the Department of Surgery of the Medical University of Vienna and the Göttlicher Heiland Hospital, Vienna. SAT was collected by excision from the periumbilical region. One year after bariatric surgery, the post-obese SAT was collected by needle biopsy of the periumbilical abdominal area. All adipose tissue samples were immediately immersed in RNAlater (Life Technologies) and stored at −80 °C.

Serum Samples and Laboratory Analysis

Blood samples were collected by venous puncture after a 12-h overnight fast. Blood samples were analyzed by the Department of Laboratory Medicine, Medical University of Vienna, for routine analysis of triglycerides, total-, HDL- and LDL-cholesterol, alanine transaminase (ALT), gamma-glutamyl transferase (GGT), glucose, insulin, C-peptide, C-reactive protein (CRP), glycosylated hemoglobin (HbA1c), and red and white blood cell counts. For ELISA analyses, blood was centrifuged at 3000g for 10 min at 4 °C and then stored at −20 °C. We used commercial ELISA kits to measure plasma concentrations of IL-6 (R&D Systems, Minneapolis, MN, USA) and serum concentrations of high-sensitivity tumor necrosis factor (Invitrogen, Thermo Fisher Scientific, Waltham, MA, USA) and myostatin (R&D Systems, Minneapolis, MN, USA) and a RIA for measuring serum adiponectin concentrations (Merck Millipore, Billerica, MA, USA). Homeostasis model assessment of insulin resistance (HOMA-IR) was calculated as the product of fasting insulin (μU/ml) and glucose (mg/dl) divided by 405.

Adipose Tissue RNA Extraction and Gene Expression Analysis

Total RNA from tissue was extracted by using the RNeasy Lipid Tissue Mini Kit (QIAGEN, Venlo, Netherlands) and by TRIzol reagent (Thermo Fisher Scientific, Waltham, MA, USA) with a tissue homogenizer, followed by RNA isolation according the manufacturer’s instructions. RT-PCR was performed in duplicates by using the TaqMan Gene Expression Assays (Applied Biosystems). Gene expression was analyzed according to the ddCt method relating gene of interest Ct values to ubiquitin C (UBC). No significant differences in the Ct values of UBC were observed between the groups. To ensure that SAT biopsies are not contaminated with dermis tissue, keratin 18 (KRT18) expression was analyzed and three positive post-obese samples (gene expression >1000 % post-obese sample in comparison to the obese sample of the same patient) were excluded. A list of used TaqMan probes is provided in the supplementary Table 1.

Statistical Analysis

Normal distribution was determined by the Shapiro-Wilk test of normality. Normally distributed data were presented as means ± SDs, otherwise as medians (interquartile ranges). Group differences were calculated by one-way ANOVA with Tukey post hoc test or Kruskal-Wallis rank sum with Dunn’s multiple comparison test, and paired t test, or Wilcoxon signed rank test for paired samples, as appropriate.

For gene expression comparison ddCt-data were investigated independently by linear mixed effects analysis of gene expression, with the fixed effects status (lean, obese, or post-obese) and plate (obese before and after bariatric surgery or lean and obese) and the patient ID as a random effect. No apparent deviations from homoscedasticity or normality were observed in the residual plot. Relative gene expression boxplots were normalized to the median of the obese group.

Data were not adjusted for multiple testing due to the study’s exploratory nature. For Pearson’s r correlation, nonparametric data were log-transformed. For the elastic net equation, the optimal settings for α (between 0 and 1) and for λ plus one standard error [22] were chosen to minimize the mean squared error using leave-one-out cross-validation. To investigate the relationship of TNF with other genes, we correlated its expression with assessed parameters in the post-obese group and performed an unbiased machine learning analysis via elastic net regularization, to check for independent predictors.

For statistical analysis, we used RStudio (version 0.99.491) [23] with R (version 3.2.2) [24] with the lme4 (1.1–10) [25] and the glmnet (2.0–2) packages [26]. Differences were considered statistically significant at two-sided values of p < 0.05.

Results

Changes in Anthropometric Measurements and Metabolic Parameters after Bariatric Surgery

Obese patients were matched to lean patients according to age and sex. Anthropometric measurements and metabolic parameters of the obese group at baseline and 1 year after bariatric surgery (post-obese) compared to the lean group are reported in Table 1. Post-obese patients significantly lost weight (mean ΔBMI 15 kg/m²) and showed improved metabolic parameters such as serum lipids (triglycerides, total cholesterol LDL-C); liver tests (ALT, GGT); and CRP concentration. Changes in glucose metabolism including insulin sensitivity and pancreatic β cell function, assessed by HOMA-IR and other OGTT-
derived indices were extensive and have already been presented elsewhere [21].

Myostatin serum levels were significantly increased in obese subjects compared to lean but normalized after weight loss (Table 1). After surgery plasma IL-6 and TNF concentrations decreased significantly, whereas adiponectin concentration increased. Although the BMI of the post-obese group was higher compared to the lean group, some metabolic parameters including plasma triglycerides, fasting glucose, insulin, and HOMA-IR were significantly lower (Table 1).

Table 1 Characteristics of lean, obese, and post-obese patients

|                      | Lean (n = 20)  | Obese (n = 31) | Post-obese (n = 31) | p value |
|----------------------|---------------|---------------|---------------------|--------|
| Sex (f/m)            | 15/5          | 24/7          | 24/7                | 0.89   |
| Age (years)          | 43 ± 9        | 42 ± 12       | 43 ± 12             | 0.03   |
| Anthropometric measures |              |               |                     |        |
| BMI (kg/m²)          | 25.5 ± 3.1*   | 46.1 ± 6.3†   | 31.1 ± 5.7‡         | <0.01  |
| WHR                  | 0.90 (0.84–0.94) | 0.91 (0.87–0.95) | 0.88 (0.85–0.92)   | 0.22   |
| Metabolic parameters |               |               |                     |        |
| Triglycerides (mg/dl)| 125.0 (95.0–180.5) | 138.0 (120.5–193.5) | 94.0 (71.5–116.5) | <0.01  |
| Total cholesterol (mg/dl) | 181.5 ± 33.9† | 165.5 ± 32.3  |                     | <0.01  |
| HDL-C (mg/dl)        | 38.0 (35.3–41.8)* | 45.0 (41.0–53.0)† | 51.0 (45.5–55.5)‡  | <0.01  |
| LDL-C (mg/dl)        | 116.3 (90.7–124.1)* | 134.0 (102.5–140.0)† | 90.8 (81.4–104.1)‡  | <0.01  |
| ALT (U/l)            | 14.0 (10.5–24.5)* | 27.0 (21.0–35.5)† | 19.5 (15.3–24.8)‡  | <0.01  |
| GGT (U/l)            | 23.0 (16.0–38.0)* | 39.0 (22.0–50.0)† | 16.0 (11.0–27.0)‡  | <0.01  |
| Fasting glucose (mg/dl) | 95.6 ± 15.9   | 94.4 ± 9.8†   | 77.8 ± 8.1‡        | <0.01  |
| Insulin (µU/ml)      | 8.0 (2.5–15.6)* | 17.1 (6.2–30.8)† | 2.0 (2.0–4.0)‡     | <0.01  |
| C-peptide (ng/ml)    | 0.5 (0.1–0.8)* | 3.9 (2.9–4.7)† | 1.9 (1.4–2.3)‡     | <0.01  |
| HOMA-IR              | 2.0 (0.5–3.2)* | 4.0 (1.4–7.8)† | 0.4 (0.4–0.9)‡     | <0.01  |
| CRP (mg/dl)          | 0.10 (0.08–0.23)* | 0.89 (0.36–1.16)† | 0.2 (0.1–0.3)‡     | <0.01  |
| Myostatin (ng/ml)    | 2.7 (2.1–3.4)* | 3.8 (2.5–4.5)† | 2.9 (2.3–3.6)      | 0.03   |
| HbA1c (%)            | 5.5 ± 0.4      | 5.3 ± 0.3     |                     | <0.01  |
| IL-6 (pg/ml)         | 3.2 (2.3–4.6)  | 1.4 (1.0–1.7) |                     | <0.01  |
| Adiponectin (µg/ml)  | 7.4 ± 2.8      | 11.2 ± 5.0    |                     | <0.01  |
| TNF (pg/ml)          | 2.7 ± 0.9      | 1.8 ± 0.6     |                     | <0.01  |
| IGF1 (ng/ml)         | 108.0 (95.0–125.5) | 127.0 (85.8–188.3) | 0.06   |
| Albumin (mg/dl)      | 41.7 ± 2.4     | 41.2 ± 2.8    |                     | 0.22   |

Values are depicted as mean ± SD or median (IQR). Statistical significance was calculated by one-way ANOVA with Tukey post hoc test or Kruskal-Wallis rank sum with Dunn’s multiple comparison test as appropriate and for HbA1c, IL-6, adiponectin, and TNF by paired t test or Wilcoxon signed rank test for paired samples. ALT alanine transaminase, CRP C-reactive protein, GGT gamma-glutamyl-transferase, HbA1c hemoglobin A1c, HDL-C high-density lipoprotein cholesterol, HOMA-IR homeostatic model assessment–insulin resistance, LDL-C low-density lipoprotein cholesterol, WHR waist to hip ratio.

In comparison, most inflammatory genes (IL1B, IL6, CCL3) in the post-obese group were dramatically downregulated. Notably, the cachexia-associated, pro-inflammatory TNF was upregulated 2.9-fold after weight loss, while expression of all interleukins (IL1B, IL6, IL10), as well as CCL3 was much lower than in the lean group (Fig. 1).

**SAT Expression of Relevant Metabolic Genes**

Since inflammatory gene expression, except TNF, was greatly reduced after surgery, we investigated the impact of weight loss on relevant metabolic genes. Compared only with the lean group, SAT ADIPOQ expression of obese patients before surgery was in trend lower (p = 0.07). In the post-obese group, ADIPOQ expression was significantly downregulated after
markers for macrophages (CD68), surface marker would reflect the catabolic processes induced by apoptosis. The M1 macrophage marker CD40 increased significantly compared to their expression before surgery. Of note, in the post-obese group SAT expression of T cell marker CD3E and of macrophage marker CD68 was even more reduced compared to the lean group (Fig. 3).

SAT Expression of Cell Surface Molecules

Since the expression of CASP3 was upregulated in response to weight loss, we investigated whether the expression of cell surface marker would reflect the catabolic processes induced by apoptosis. The M1 macrophage marker CD40 did not differ in mRNA expression between the groups and seemed unaffected by weight loss. In contrast, SAT expression of markers for macrophages (CD68), T cells (CD3E), endothelial cells (CD144), and antigen-presenting cells (HLA-DR) decreased significantly compared to their expression before surgery. Of note, in the post-obese group SAT expression of T cell marker CD3E and of macrophage marker CD68 was even more reduced compared to the lean group (Fig. 3).

SAT Expression of Growth Factors

We next analyzed the SAT expression of growth factors relevant to obesity. The fibroblast growth factor 1 (FGF1), insulin growth factor 1 (IGF-1), and angiogenic vascular endothelial growth factor C (VEGFC) were downregulated after bariatric intervention (Fig. 4). Expression of FGF1 and IGF1 was even below the values of the lean group.

Correlation Analysis of TNF Gene Expression after Bariatric Surgery

One of the most noteworthy findings in the post-obese group was that TNF expression was markedly upregulated upon weight loss (Fig. 1). Therefore, we investigated factors modulating TNF expression in serum or on gene expression level. By calculating Pearson’s correlation coefficient, we observed a positive correlation between TNF expression, fasting blood glucose, and CASP3 expression and a negative correlation with IGF1, PLIN1, PPARG, and SLC2A4 expression (Table 2). To identify independent predictors of TNF expression, we performed a linear regression analysis with an elastic net regularization, in which all parameters were included. The analysis showed that fasting glucose levels (mg/dl), CASP3, and CD40 increase, whereas SLC2A4 decreases TNF expression in the post-obese group.

Discussion

Our present work aimed to investigate SAT expression of relevant inflammatory and metabolic genes of morbidly obese patients before and 1 year after bariatric surgery in comparison to lean subjects. Even though the mean BMI of patients in the post-obese group was still higher compared to the lean control group, most metabolic risk factors, such as insulin resistance, hyperlipidemia, and systemic inflammation, changed to such an extent that many of the analyzed parameters in serum differed even from the lean control group. Interestingly, analysis of adipose tissue inflammation-associated genes showed that gene expression profile of the post-obese group was significantly different in comparison to the obese and even the lean control group and pointed to reduced inflammation. We further showed that weight loss affected several genes relevant to lipolysis, apoptosis, and also growth factors with a role in cachexia. Accordingly, it seems that the near to normal weight achieved after bariatric surgery reflects a cachexia-like state rather than a healthy lean phenotype, particularly indicated by the extensive upregulation of TNF expression in the post-obese group.

Macrophase-associated inflammatory cytokines like IL1B, IL6, and CCL3 were all upregulated in obese SAT [27-29], but markedly downregulated after bariatric surgery, concordant with other data [30, 31]. Interestingly, the anti-inflammatory IL10 was downregulated upon weight loss. The finding that TNF was markedly upregulated contrasts other data, however, in those studies, the BMI change in...
response to weight loss was lower, the follow-up time was shorter, or the cohorts included diabetic patients [30, 32].

TNF was originally described as the cachexia-inducing factor and termed cachectin indicating a Janus-type function [33]. It is known to mediate lipolysis and insulin resistance by downregulation of PLIN1 [7] and CIDEA expression [8]. TNF was described to cause apoptosis of adipocytes in vitro in a CASP3-dependent manner [34]. Notably, CASP3 expression is higher in SAT in obesity in our study as well as in other studies [35]. Since the number of adipocytes in adults is described to be unchanged upon weight gain or weight loss [36], CASP3 upregulation might be explained by increased apoptosis of inflammatory immune cells from the stromal vascular fraction [37], as evidenced by the remarkable decrease in T cell marker CD3E, pan-macrophage marker CD68, endothelial cell marker CD144 and antigen-presenting cell marker HLA-DR. In our post-obese group, CASP3 expression in adipose tissue is even higher than in the obese group, clearly indicating a catabolic state.

TNF inhibits adipogenesis by downregulating PPAR expression in cultured human adipocytes [38]. We detected increased lipolysis and reduced adipogenesis in our cohort. The downregulation of metabolic markers ADIPOQ, IRS2, PPARG, and SLC2A4 (GLUT-4) expression after weight loss indicates reduced metabolism in adipose tissue. A study performed in rats showed similar results after RYGB [39].
PPARG downregulation suggests an inhibition of adipogenesis and concomitant insulin resistance in SAT during weight loss [40]. Other studies also showed a decrease in PPARG after hypocaloric diet or 3 months after bariatric surgery [41–43]. Other adipogenesis-related genes such as IGF1 [44] and FGF1 were also significantly downregulated in the post obese group. The preadipocyte differentiation marker FGF1 was downregulated in post-obese SAT, contrary to the findings of Mejhert et al. who did not detect any differences in FGF1 secretion after 10 weeks of diet-induced weight loss [45]. However, the weight loss was, notably, not as pronounced as we observed 1 year after bariatric surgery.

Although insulin pathway genes were downregulated, whole-body insulin sensitivity was restored in the post-obese group as suggested by the HOMA-IR and as noted previously [21]. Surprisingly, TNF expression in post-obese could be predicted by fasting glucose, although fasting glucose values were already lower in comparison to the lean control group. Interestingly, TNF expression in SAT after bariatric surgery is independent of whole-body insulin resistance, contrary to the obese state. Local insulin resistance seems to occur in SAT, similar to cachectic states. In contrast to a previous study [46], the pro-inflammatory M1 macrophage marker CD40 was not

| Table 2 | Correlations and elastic net regression for TNF gene expression in post-obese SAT |
|---------|-----------------------------------------------|
|         | r    | p value | r    | p value |
| Age (years) | 0.02 | 0.93 | Gene expression |  |
| BMI (kg/m²) | 0.01 | 0.95 | ADIPOQ | −0.38 | 0.06 |
| WHR | 0.02 | 0.94 | CASP3 | 0.56 | <0.01 |
| Serum parameters |  |
| Triglycerides (mg/dl) | 0.20 | 0.33 | CD144 | −0.29 | 0.14 |
| Total cholesterol (mg/dl) | −0.23 | 0.25 | CD3E | 0.30 | 0.13 |
| HDL-C (mg/dl) | −0.26 | 0.20 | CD40 | 0.34 | 0.09 |
| LDL-C (mg/dl) | −0.25 | 0.21 | CD68 | −0.29 | 0.15 |
| ALT (U/l) | 0.23 | 0.21 | CIDEA | −0.37 | 0.06 |
| GGT (U/l) | 0.31 | 0.13 | FGF1 | −0.33 | 0.10 |
| Glucose (mg/dl) | 0.39 | 0.04 | FGF1 | −0.43 | 0.03 |
| Insulin (μU/ml) | 0.00 | 0.98 | HLA-DR | 0.10 | 0.63 |
| C-peptide (ng/ml) | −0.03 | 0.87 | IL1B | −0.17 | 0.42 |
| HOMA-IR | 0.02 | 0.91 | IL6 | −0.33 | 0.13 |
| CRP (mg/dl) | 0.12 | 0.56 | IRS2 | −0.15 | 0.47 |
| HbA1c (%) | −0.03 | 0.90 | PLIN1 | −0.44 | 0.03 |
| Myostatin (ng/ml) | 0.22 | 0.37 | PPARG | −0.48 | 0.01 |
| IL-6 (pg/ml) | 0.26 | 0.20 | SLC2A4 | −0.54 | <0.01 |
| Adiponectin (μg/ml) | 0.03 | 0.90 | VEGFC | −0.27 | 0.18 |
| TNF (pg/ml) | 0.07 | 0.72 | Selected variables | B coefficients |
| IGF1 (ng/ml) | −0.25 | 0.20 | Glucose (mg/ml) | 0.002 |
| Albumin (mg/dl) | 0.24 | 0.21 | CASP3 (a.u.) | 0.308 |
| Elastic net regression |  |
| Glucose (mg/ml) | 0.002 |
| CD144 (a.u.) | 0.308 |
| CD3E (a.u.) | 0.033 |
| ALT (U/l) | <0.85 |
| C-reactive protein, GGT gamma-glutamyl-transferase, HbA1c hemoglobin A1c, HDL-C high-density lipoprotein cholesterol, HOMA-IR homeostatic model assessment–insulin resistance, LDL-C low-density lipoprotein cholesterol, WHR waist to hip ratio, a.u. arbitrary units

Significant correlations are highlighted in italics. B coefficients represent the unstandardized regression coefficient of the independent variables, which describe the ddCt values of TNF via elastic net regression. Elastic net parameters were chosen to minimize the mean squared error of the linear regression as following: the relative strength of the L1 and L2 penalty term \( \alpha = 0.86 \) and the regression penalty \( \lambda = 0.30 \). The intercept of the regression was 0.950

\( r \) Pearson correlation coefficient, \( p \) significance level, ALT alanine transaminase, CRP C-reactive protein, GGT gamma-glutamyl-transferase, HbA1c hemoglobin A1c, HDL-C high-density lipoprotein cholesterol, HOMA-IR homeostatic model assessment–insulin resistance, LDL-C low-density lipoprotein cholesterol, WHR waist to hip ratio, a.u. arbitrary units
reduced in the post-obese group, although the pan-macrophage marker CD68 expression was downregulated. The increased CD40/CD68 ratio together with the down-regulation of PPARG and ADIPOQ suggest a shift towards local insulin resistance inducing M1-like macrophages in SAT [47–50]. M1 macrophages are the primary source of TNF and seem to orchestrate insulin resistance [51]. Interestingly, although the expression of the immune cell marker CD40 does not change significantly, elastic net revealed TNF expression acts as a positive predictor. Therefore, CD40-positive cells could be a source of the TNF upregulation in the SAT of post-obese patients. Of note, an increased apoptosis rate may also cause TNF up-regulation by the so-called apoptosis-induced apoptosis, where dying cells secrete TNF, which then in turn induce even more apoptosis [52]. A proposed mechanism for TNF modulation of lipolysis in adipose tissue after weight loss is described in Fig. 5.

Weight loss after bariatric surgery can sometimes lead to a pronounced reduction of fat and fat-free mass similar to cachexia [17]. Muscle wasting is relevant to cachexia; however, whole body muscle mass changes were not analyzed. Since myostatin (MSTN) levels correlate negatively with muscle mass and high circulating levels of MSTN were observed in muscle wasting conditions [53, 54], MSTN was used as surrogate marker of skeletal muscle mass. To our knowledge, we are the first to report changes in myostatin serum concentration after weight loss induced by bariatric surgery. Consistent with the findings of Park et al. in muscle biopsies of obese subjects ~1 year after bariatric surgery, we observed a significant decrease in circulating myostatin levels upon weight loss, which approximated the level of the lean group [55], suggesting that muscle wasting is not too advanced.

Regarding other growth factors related to both obesity and cachexia, our group showed that serum IGF-1 concentration increases in trend after surgery and is associated with a risk for developing post-load hypoglycemia 2 h after a standardized glucose challenge [21]. Downregulated IGF1 in SAT in the post-obese group indicates that IGF-1-concentration is uncoupled from SAT expression, since serum IGF-1 is primarily hepatic [56].

Other examples of uncoupled SAT expression-serum concentration include circulating adiponectin and TNF. The increase in adiponectin concentration in serum 1 year after surgery did not reflect an increase in SAT ADIPOQ expression, although SAT is believed to be the main source of serum adiponectin [57], suggesting that in the post-obese, other fat depots, most likely bone marrow adipose tissue, significantly contributes to adiponectin serum levels [58]. Also, others observed that circulating adiponectin increases, while IL-6 and TNF concentration decreases upon weight loss [59, 60]. However, SAT IL6 expression is described to be connected with serum levels in humans while TNF expression is not—meaning that TNF primarily acts in a paracrine or autocrine manner [61].

A limitation to our study is that the data merely present a “snapshot” during weight loss, as we did not include multiple time points after bariatric surgery. It would be interesting to know whether expression profiles after 5 or 10 years will resemble a healthy lean state in contrast to the catabolic state we observed in our study. An additional limitation of this study is that due to obvious reasons, we could only collect subcutaneous and not omental adipose tissue during follow-up. The amount of collected tissue by needle biopsy was very limited. Therefore, only mRNA expression could be investigated but neither histology nor protein expression. Adipose tissue samples were collected by excision during surgery for the lean and obese group and by needle biopsy in the post-obese group. Contradictory data are published on whether adipose tissue sampling affects gene expression analysis [77,78], yet we did not observe any significant differences between surgical excision and needle biopsy either (data not shown). For an inclusive statistical analysis, we performed a linear mixed effects model, taking into account the fact that due to sample size, considerations loss of power in comparing the lean with the obese group would occur.

Most studies focusing on bariatric surgery follow-up mainly investigated changes in serum parameters, whereas only few investigated changes in the expression of adipose tissue inflammation and cachexia-related genes. A major strength of our study is the thorough characterization of systemic and local adipose tissue changes after weight loss and the comparison to the lean state, as well as the novel finding that upon bariatric surgery, a state similar to cachexia seems to develop in SAT. Similarities and differences between post-bariatric weight loss as evaluated in this study and published data on cachexia [17, 62, 63] are presented in supplementary Table 2.

In summary, our data suggest that in response to surgery-induced weight loss, upregulated TNF expression leads to increased lipolysis via PLIN1 downregulation, decreased adipogenesis via PPARG downregulation and even increased adipocyte turnover via CASP3 upregulation. Concomitant with lipolysis, local insulin resistance also occurs in cachexia and was reflected in our study by the downregulation of PLIN1, CIDÉA, SLC2A4, ADIPOQ, IRS2, and PPARG. Thus, the profound weight loss caused a specific pattern in SAT gene expression, which let us conclude that the post-obese SAT reflects a cachexia-like state rather than healthiness. For a more in-depth analysis of the biological processes occurring in different human fat depots during weight loss, the mechanisms through which these changes contribute to whole-body metabolism need to be investigated in further studies.
Acknowledgements  Open access funding provided by Medical University of Vienna. This study was funded by the Federal Ministry of Economy, Family, and Youth and the National Foundation for Research, Technology and Development (to T.M.S.). We are grateful to Florian Klinglmüller from the Medical Statistics Department of the Medical University of Vienna for providing consultancy on statistical analysis issue, to Lilliana Ionasz and Erika Novotny for their excellent technical assistance in performing the ELISAs, and to Dr. Monika Gräßl for help with recruiting the lean patients.

Compliance with Ethical Standards

Conflict of Interest  All authors declare that they have no conflict of interest.

Ethical Approval/Human Rights  All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed Consent  All participants provided informed written consent prior to their inclusion in the study. The trial has been approved by the Ethics Committee of the Medical University of Vienna (EK-Nr. 488/2006, EK 275/2006 and EK-Nr. 963/2009) and by the Ethics Committee of the Göttinger Heiland Hospital (EK-Nr. E10-N01–01) and was conducted at the Clinical Research Unit of the Division of Endocrinology and Metabolism, Department of Medicine III, Medical University of Vienna.

Disclosure Statement  The authors declare that they have no conflict of interest.

Open Access  This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Jin C, Flavell RA. Innate sensors of pathogen and stress: linking inflammation to obesity. J Allergy Clin Immunol. 2013;132:287–94.
2. Shea J, French CR, Bishop J, et al. Changes in the transcriptome of abdominal subcutaneous adipose tissue in response to short-term overfeeding in lean and obese men. Am J Clin Nutr. 2009;89:407–15.
3. Medzhitov R. Origin and physiological roles of inflammation. Nature. 2008;454:428–35.
4. Rausch ME, Weisberg S, Vardhana P, et al. Obesity in C57BL/6J mice is characterized by adipose tissue hypoxia and cytotoxic T-cell infiltration. Int J Obes. 2008;32:451–63.
5. Nishimura S, Manabe I, Nagasaki M, et al. CD8+ effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity. Nat Med. 2009;15:914–20.
6. Lumeng CN, Deyoung SM, Bodzin JL, et al. Increased inflammatory properties of adipose tissue macrophages recruited during diet-induced obesity. Diabetes. 2007;56:16–23.
7. Rydén M, Arvidsson E, Blomqvist L, et al. Targets for TNF-alpha-induced lipolysis in human adipocytes. Biochem Biophys Res Commun. 2004;318:168–75.
8. Nordström EA, Rydén M, Backlund EC, et al. A human-specific role of cell death-inducing DFFA (DNA fragmentation factor-alpha)-like effector a (CIDEA) in adipocyte lipolysis and obesity. Diabetes. 2005;54:1726–34.
9. Puri V, Ranjit S, Konda S, et al. Cidea is associated with lipid droplets and insulin sensitivity in humans. Proc Natl Acad Sci U S A. 2008;105:7833–8.
10. Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun. 1999;257:79–83.
11. Weisberg SP, McCann D, Desai M, et al. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest. 2003;112:1596–608.
12. Xu H, Barnes GT, Yang Q, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest. 2003;112:1821–30.
13. Lee YH, Petkova AP, Granneman JG. Identification of an adipogenic niche for adipose tissue remodeling and restoration. Cell Metab. 2013;18:555–67.
14. Schauer PR, Kashyap SR, Wolski K, et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med. 2012;366:1567–76.
15. Courcouulas AP, Goodpaster BH, Eagleton JK, et al. Surgical vs medical treatments for type 2 diabetes mellitus: a randomized clinical trial. JAMA Surg. 2014;149:707–15.
16. Adams TD, Davidson LE, Litwin SE, et al. Health benefits of gastric bypass surgery after 6 years. JAMA. 2012;308:1122–31.
17. Nicoletti CF, Camelio Jr JS, dos Santos JE, et al. Bioelectrical impedance vector analysis in obese women before and after bariatric surgery: changes in body composition. Nutrition. 2014;30:569–74.
18. Fanzani A, Conraads VM, Penna F, et al. Molecular and cellular mechanisms of skeletal muscle atrophy: an update. J Cachexia Sarcopenia Muscle. 2012;3:163–79.
19. Fenzl A, Itariu BK, Kosi L, et al. Circulating betatrophin correlates with atherogenic lipid profiles but not with glucose and insulin levels in insulin-resistant individuals. Diabetologia. 2014;57:1204–8.
20. Amor M, Moreno-Viedma V, Sarabi A, et al. Identification of matrix metalloproteinase-12 as a candidate molecule for prevention and treatment of cardiometabolic disease. Mol Med. 2016;22
21. Itariu BK, Zeya M, Prager G, et al. Insulin-like growth factor 1 predicts post-load hypoglycemia following bariatric surgery: a prospective cohort study. PLoS One. 2014;9:e94613.
22. Krstačić D, Buturovic LJ, Leahy DE, et al. Cross-validation pitfalls when selecting and assessing regression and classification models. J Cheminform. 2014;6:10.
23. Team RS. RStudio: integrated development environment for R. RStudio, Inc.; 2015
24. Team RC. R: a language and environment for statistical computing. R Foundation for Statistical Computing; 2015
25. Bates D, Mächler M, Bolker B, et al. Fitting linear mixed-effects models using lme4. arXiv:2014
26. Zou H, Hastie T. Regularization and variable selection via the elastic net. J R Stat Soc Ser B Stat Methodol. 2005;67:301–20.
27. Huber J, Kiefer FW, Zeya M, et al. CC chemokine and CC chemokine receptor profiles in visceral and subcutaneous adipose tissue are altered in human obesity. J Clin Endocrinol Metab. 2008;93:3215–21.
28. Gerhardt CC, Romero IA, Cancell R, et al. Chemokines control fat accumulation and leptin secretion by cultured human adipocytes. Chemokines control fat accumulation and leptin secretion by cultured human adipocytes 175.; 0200
29. Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol. 2006;6:772–83.

30. Pardina E, Ferrer R, Baena-Fustegueras JA, et al. Only C-reactive protein, but not TNF-alpha or IL6, reflects the improvement in inflammation after bariatric surgery. Obes Surg. 2012;22:131–9.

31. Dankel SN, Fadnes DJ, Stavrum A-K, et al. Switch from stress response to homeobox transcription factors in adipose tissue after profound fat loss. PLoS One. 2010;5:e11033.

32. Moschen AR, Molnar C, Geiger S, et al. Anti-inflammatory effects of excessive weight loss: potent suppression of adipocyte interleukin 6 and tumour necrosis factor alpha expression. Gut. 2010;59:1259–64.

33. Oliff A, Defeo-Jones D, Boyer M, et al. Tumors secreting human TNF/cachectin induce cachexia in mice. Cell. 1987;50:555–63.

34. Qian H, Hausman DB, Compton MM, et al. TNFalpha induces and inhibits caspase 3-dependent adipocyte apoptosis. Biochem Biophys Res Commun. 2001;284:1176–83.

35. Tinahones FJ, Coín Aragüez L, Murri M, et al. Tumors secreting human TNF/cachectin induce cachexia in mice. Cell. 1987;50:555–63.

36. Spalding KL, Arner E, Westermark PO, et al. Dynamics of fat cell turnover in humans. Nature. 2008;453:783–7.

37. Rydén M, Uzunel M, Hård JL, et al. Transplanted bone marrow-derived cells contribute to human adipogenesis. Cell Metab. 2015;22:408–17.

38. Hube F, Hauner H. The two tumor necrosis factor receptors mediate opposite effects on differentiation and glucose metabolism in human adipocytes in primary culture. Endocrinology. 2000;141:2582–8.

39. Bonhomme S, Guijarro A, Keslacy C, et al. Gastric bypass upregulates insulin signaling pathway. Nutrition. 2011;27:73–80.

40. Ahmedian M, Suh JM, Hah N, et al. PPARgamma signaling and BCL2 inhibition in human adipose tissue: a potential relationship with insulin signaling alteration. Diabetes Care. 2013;36:513–21.

41. Vidal-Puig A, Jimenez-Liñan M, Lowell BB, et al. Regulation of PPAR gamma gene expression by nutrition and obesity in rodents. J Clin Invest. 1996;97:2553–61.

42. Bastard J-P, Hainque B, Dusserre E, et al. Peroxisome proliferator activated receptor-γ, leptin and tumor necrosis factor-α mRNA expression during very low calorie diet in subcutaneous adipose tissue in obese women. Diabetes Metab Res Rev. 1999;15:92–8.

43. Leyvraz C, Verdugo C, Suter M, et al. Changes in gene expression profile in human subcutaneous adipose tissue during significant weight loss. Obes Facts. 2012;5:440–51.

44. Garten A, Schuster K, Kiesel W. The insulin-like growth factors in adipogenesis and obesity. Endocr Metab Clin N Am. 2012;41:283–95. v-vi

45. Mejhet N, Galitzky J, Pettersson AF, et al. Mapping of the fibroblast growth factors in human white adipose tissue. J Clin Endocrinol Metab. 2010;95:2451–7.

46. Aron-Wisnewsky J, Tordjman J, Poitou C, et al. Human adipose tissue macrophages: m1 and m2 cell surface markers in subcutaneous and omental depots and after weight loss. J Clin Endocrinol Metab. 2009;94:4619–23.

47. Hevener AL, Olefsky JM, Reichart D, et al. Macrophage PPAR gamma is required for normal skeletal muscle and hepatic insulin sensitivity and full antidiabetic effects of thiazolidinediones. J Clin Invest. 2007;117:1658–69.

48. Odegaard JJ, Ricardo-Gonzalez RR, Goforth MH, et al. Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance. Nature. 2007;447:1116–20.

49. Kumada M, Kihara S, Ouchi N, et al. Adiponectin specifically increased tissue inhibitor of metalloproteinase-1 through interleukin-10 expression in human macrophages. Circulation. 2004;109:2046–9.

50. Ohashi K, Parker JL, Ouchi N, et al. Adiponectin promotes macrophage polarization toward an anti-inflammatory phenotype. J Biol Chem. 2010;285:6153–60.

51. Peluso I, Palmery M. The relationship between body weight and inflammation: lesson from anti-TNF-alpha antibody therapy. Hum Immunol. 2016;77:47–53.

52. Perez-Garrio A, Fuchs Y, Steller H. Apoptotic cells can induce non-autonomous apoptosis through the TNF pathway. Elife. 2013;2:e01004.

53. Yarasheski KE, Bhasin S, Sinha-Hikim I, et al. Serum myostatin-immunoreactive protein is increased in 60–92 year old women and men with muscle wasting. J Nutr Health Aging. 2002;6:343–8.

54. Tsiova MN, Oikonomou D, Vittas S, et al. Plasma myostatin is only a weak predictor for weight maintenance in obese adults. Exp Clin Endocrinol Diabetes. 2015;123:466–72.

55. Park JJ, Berggren JR, Hulver MW, et al. GRB14, GPD1, and GDF8 as potential network collaborators in weight loss-induced improvements in insulin action in human skeletal muscle. Physiol Genomics. 2006;27:114–21.

56. Jones JL, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endo Rev. 1995;16:3–34.

57. Lihn AS, Bruun JM, He G, et al. Lower expression of adiponectin mRNA in visceral adipose tissue in lean and obese subjects. Mol Cell Endocrinol. 2004;219:9–15.

58. Cawthorn WP, Scheller EL, Learman BS, et al. Bone marrow adipose tissue is an endocrine organ that contributes to increased circulating adiponectin during caloric restriction. Cell Metab. 2014;20:368–75.

59. Yamauchi T, Kamon J, Waki H, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med. 2001;7:941–6.

60. Kern PA, Ranganathan S, Li C, et al. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab. 2001;280:E745–50.

61. Mohamed-Ali V, Goodrick S, Rawesh A, et al. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor, in vivo. Journal of Clinical Endocrinology & Metabolism. 1997;82:4196–200.

62. Batista JR ML, Neves RX, Peres SB, et al. Heterogeneous time-dependent response of adipose tissue during the development of cancer cachexia. J Endocrinol. 2012;215:363–73.

63. Noguchi Y, Yoshikawa T, Marat D, et al. Insulin resistance in cancer patients is associated with enhanced tumor necrosis factor-alpha expression in skeletal muscle. Biochem Biophys Res Commun. 1998;253:887–92.